Miralaxpolyethylene glycol

According to the FDA label: Uses relieves dryness of the eye. for the temporary relief of burning, irritation and discomfort due to dryness of the eye or exposure to the wind and sun. may be used as a protectant against further irritation.

88,434 adverse event reports submitted to the FDA (2003–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Miralax in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Miralax adverse event reports by reporter sex
SexReports
Female48,345
Male31,415
Unknown251

By Age Group

View age group data as a table
Miralax adverse event reports by reporter age group
Age groupReports
0-175,477
18-342,637
35-493,551
50-649,480
65-7411,307
75+17,077

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Miralax. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Miralax adverse event reports by reported outcome
OutcomeReports
Non-Serious54,062
Other Serious20,202
Hospitalization19,125
Death5,562
Life-Threatening1,750
Disability1,453

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Miralax. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Miralax adverse event reports by year
YearReports
20031
2004203
2005247
2006305
2007327
2008496
2009624
2010759
2011958
20122,207
20134,115
20144,034
20156,832
20168,844
20178,276
20187,658
20196,757
20206,681
20216,002
20225,615
20235,156
20245,041
20256,021
2026 (partial)1,275

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Miralax

In FDA adverse event reports that mention Miralax, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026